Editorial: New drugs for HIV: quo vadis?

Affiliations

¹ Divisions of Clinical Pharmacology and Infectious Diseases, School of Medicine and Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
² UNC Eshelman School of Pharmacy, UNC Center for AIDS Research, UNC Chapel Hill, North Carolina, USA.

Editorial

Charles W Flexner et al. Curr Opin HIV AIDS. 2022.

. 2022 Jan 1;17(1):1-3.

doi: 10.1097/COH.0000000000000710.

¹ Divisions of Clinical Pharmacology and Infectious Diseases, School of Medicine and Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
² UNC Eshelman School of Pharmacy, UNC Center for AIDS Research, UNC Chapel Hill, North Carolina, USA.

No abstract available

References

1. UNAIDS. Global HIV & AIDS statistics – Fact sheet. Available at: http://https://www.unaids.org/en/resources/fact-sheet . [Accessed 20 October 2021]
1. Flexner C, Clayden P, Venter WDF. Why a universal antiretroviral regimen? Curr Opin HIV/AIDS 2017; 12:315–317.
1. Paton NI, Musaazi J, Kityo C, et al. Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV. N Engl J Med 2021; 385:330–341.
1. Flexner C, Owen A, Siccardi M, Swindells S. Long-acting drugs and formulations for the treatment and prevention of HIV. Int J Antimicrob Agents 2021; 57:106220.
1. Bares SH, Scarsi KK. A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV. Curr Opin HIV AIDS 2022; 17:22–31.